WO2007145239A1 - Agent anti-fatigue contenant une composition d'acides aminés - Google Patents

Agent anti-fatigue contenant une composition d'acides aminés Download PDF

Info

Publication number
WO2007145239A1
WO2007145239A1 PCT/JP2007/061879 JP2007061879W WO2007145239A1 WO 2007145239 A1 WO2007145239 A1 WO 2007145239A1 JP 2007061879 W JP2007061879 W JP 2007061879W WO 2007145239 A1 WO2007145239 A1 WO 2007145239A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatigue
weight
parts
amino acid
acid composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/061879
Other languages
English (en)
Japanese (ja)
Inventor
Masato Saito
Hiroyuki Arita
Hiroshi Tsuchita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Dairies Corp
Original Assignee
Meiji Dairies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corp filed Critical Meiji Dairies Corp
Priority to JP2008521230A priority Critical patent/JP5775657B2/ja
Publication of WO2007145239A1 publication Critical patent/WO2007145239A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Anti-fatigue agent containing amino acid composition
  • the present invention relates to a fatigue inhibitor containing an amino acid composition having a specific type of amino acid strength.
  • Fatigue is broadly classified into acute fatigue and chronic fatigue when classified from the onset, and the former occurs in units of several minutes and several hours and often recovers after a relatively short rest. The latter is a force that recovers for several days without recovery when acute fatigue accumulates, or weekly for long periods. There is.
  • these methods may include administration of certain drugs or supplements.
  • drug administration diagnosis and prescribing by a doctor are necessary, which is complicated.
  • dietary supplements as a supplement are simple and easy to incorporate into daily life.
  • research and development and product development have been promoted, and supplement factories are steadily expanding.
  • fatigue recovery supplements such as citrate, vitamins, and coenzyme Q10 are also sold at convenience stores.
  • the effect of recovering the fatigue of each of the above-mentioned muscle fatigue and nerve fatigue has not been clarified, and there is still no clear method for satisfying both of them in practice. Not obtained.
  • Patent Document 1 discloses an amino acid composition that quickly recovers mental fatigue such as fatigue of muscles themselves and fatigue associated therewith.
  • Non-Patent Document 1 discloses that amino acids such as proline, glycine, and alanine are significantly consumed and decreased in humans who have been subjected to a long-term bicycle load.
  • Non-Patent Document 2 discusses changes in the concentration of plasma components with and without carbohydrate supplementation during exercise. This document shows that plasma concentrations of glycine, allan, lysine, threonine, and histidine are decreased, and in particular, the decrease rate of histidine is large.
  • Non-Patent Document 3 also discloses the results of studies on changes in the concentrations of various plasma components in a system with and without feeding during exercise. Here, it is disclosed that the concentration reduction rate of tributophane is particularly large!
  • Patent Document 1 Japanese Patent No. 2518692
  • Patent Document 2 JP-A-8-198748
  • Patent Document 3 Reissue 2002Z034257
  • Non-Patent Document 1 G. Ahlborg et al., The Journal of Clinical Investigat ion, 53rd, April 1974, ⁇ .1080-1090
  • Non-Patent Document 2 T. L. Bazare et al. ( ⁇ ⁇ . Bazzare et al), Journal of the American College of Nutrition, 1992, Vol. 11, No. 5, p. 501-511
  • Non-Patent Document 3 A. H. Forslund et al., Am. J. Physiol Endocrinol Metab., 2000, 278, p.857-867
  • these conventional amino acid yarns and composites are mainly intended to improve athletic ability, and have not yet been sufficiently examined in terms of anti-fatigue effect and fatigue prevention.
  • technologies that are particularly effective for recovery from fatigue and prevention but in any case, studies on the effects of preventing muscle fatigue and nerve fatigue are insufficient, and it is difficult to say that they have been solved.
  • these conventional amino acid compositions have to supply various kinds and a large amount of amino acids as a composition, which inevitably has a problem of high cost.
  • the present inventors have found that an amino acid composition having an unprecedented composition and quantity ratio can provide an effect of preventing fatigue that has been insufficient in the past. Was completed.
  • an object of the present invention is to provide an anti-fatigue agent containing an amino acid composition having a specific type of specific amount of amino acid.
  • the present invention provides an anti-fatigue agent comprising an amino acid composition having the following amino acid strength:
  • an anti-fatigue agent containing the following amino acids in addition to the amino acid yarn composition having the above-described structure is preferable:
  • an anti-fatigue agent containing the following amino acids in addition to the amino acid yarn composition having the above structure is preferable:
  • the present invention relates to the anti-fatigue agent described above, which simultaneously prevents both muscle fatigue and nerve fatigue.
  • the present invention also relates to the anti-fatigue agent as described above, wherein muscle fatigue is evaluated by measuring the amount of behavior, and nerve fatigue is evaluated by measuring blood biomarkers.
  • the present invention is that the behavioral amount of the non-administered group is 100 or more when the behavioral amount of the non-administration group is 100), and the evaluation by the blood biomarker measurement When the measured concentration of the non-administered group is 100, the measured concentration (relative value) of the administered group is 96 or less, and the anti-fatigue agent is evaluated to have an effect of preventing muscle fatigue and nerve fatigue.
  • the composition used for the anti-fatigue agent of the present invention is an amino acid composition having a composition and quantity ratio that has not been conventionally used. Thereby, it is possible to obtain a high effect for preventing fatigue which has been insufficient in the past. That is, for the first time according to the present invention, both actual muscle fatigue and nerve fatigue can be prevented simultaneously.
  • the amount of amino acids is less than that of conventional amino acid compositions, and high! ⁇ Because it is possible to obtain the effect of preventing fatigue, the number of raw material types required for preparation is reduced, and the effect is high both industrially and economically.
  • a high fatigue prevention effect can be obtained with a smaller amount of amino acid than in the conventional amino acid composition, the effect is high both industrially and economically.
  • the amount of each amino acid used is small, and when this is prepared so as to be suitable for beverages, etc., a low-capacity beverage can be measured as a beverage. In particular, it becomes effective as a portable beverage such as a speed link.
  • amino acid composition contained in the anti-fatigue agent of the present invention those containing the following amino acids in the following quantitative ratios are preferred: 30 to 200 parts by weight of proline;
  • the amino acid composition having the above composition preferably further contains the following amino acids.
  • amino acid yarn and composition further contain the following amino acids.
  • the amino acid composition contained in the fatigue inhibitor of the present invention preferably contains the following amino acids in the following quantitative ratios.
  • Glycine 75- L 10 parts by weight
  • an anti-fatigue agent containing an amino acid composition consisting of these nine amino acids is preferred.
  • the amino acid yarn composition contained in the anti-fatigue agent of the present invention preferably contains the following amino acids in the following quantitative ratios.
  • Glycine 75- L 10 parts by weight
  • Tribfan fan 25 to 65 parts by weight of Tribfan fan
  • an anti-fatigue agent comprising an amino acid composition having only 9 types of amino acid power is preferred.
  • the amino acid composition contained in the anti-fatigue agent of the present invention the following amino acid is preferably used in the following quantitative ratio. Is included.
  • tyrosine is more preferably 35 to 55 parts by weight.
  • the anti-fatigue agent of the present invention has an anti-fatigue effect on both muscular fatigue and nerve fatigue by two types of evaluation systems: measurement of the amount of behavior during fatigue and measurement of one blood biomarker during fatigue. It is evaluated.
  • Evaluation by the behavioral amount measurement is performed by, for example, applying exercise load to the two groups of the administration group (administration of amino acid composition) and the non-administration group (control group) with a treadmill or the like.
  • the behavioral amount was measured, and the relative behavioral amount of the administration group was calculated when the behavioral amount of the non-administration group was taken as 100.
  • the amount of activity in the administration group exceeds 100, preferably 110 or more, more preferably 120 or more, particularly preferably 190 or more, the administered amino acid composition is effective in preventing muscle fatigue. It can be evaluated that it has.
  • the action amount (relative value) of the administration group is higher in the effect of preventing muscle fatigue as the value is larger.
  • blood biomarker measurement is performed by applying exercise load to the two groups, an administration group (administration of amino acid string and adult) and a non-administration group (control group) using a treadmill or the like. Blood was collected after a lapse of a certain period of time, and the concentrations of blood marker in the two groups were measured, and the relative measured concentration of the administration group was calculated when the measurement concentration of the non-administration group was taken as 100.
  • the measured concentration (relative value) of the administration group is less than 100 If it is 96 or less, it can be evaluated as having an effect of preventing nerve fatigue.
  • the measured concentration (relative value) of the administration group when the measured concentration (relative value) of the administration group is preferably 95 or less, more preferably 80 or less, it can be evaluated as having an effect of preventing nerve fatigue.
  • IFN-y when the measured concentration (relative value) of the administration group is preferably 60 or less, more preferably 45 or less, it can be evaluated as having an effect of preventing nerve fatigue.
  • IL-10 when used as an index, it can be evaluated that it has an effect of preventing nerve fatigue when the measured concentration of the administration group is preferably 70 or less, more preferably 50 or less.
  • the measured concentration (relative value) in the administration group is more effective in preventing nerve fatigue as the value is smaller. Can be evaluated as high.
  • Mechionin preferably 0.3 to 0.7 mol 0/0, more preferably 0.4 to 0.6 moles 0 / 0
  • Asuparagin acid preferably 0.1 to 0.3 mole 0/0
  • taurine preferably 3 mole 0/0 or less
  • phosphoric acid ethanolamine preferably not more than 2 mol%
  • cystine preferably 0.5 mol% or less
  • J8- Aranin favored properly below 1 mol%)
  • Amino acid preferably not more than 0.5 mol%), ol - Chin or ethanol ⁇ Min (preferably 3 moles 0 / 0 or less), ammonia (preferably 2 mole 0/0 or less), 1-methylhistidine (preferably not more than 3 mol%), 3-methylhistidine (preferably may contain 1 mol% or less). It is particularly preferred that the amino acid in the amino acid composition used in the present invention is an L-amino acid.
  • Each amino acid used in the present invention is preferably a single product having a high purity.
  • These amino acids can also be used in the form of their physiologically acceptable salts.
  • the above-mentioned commercially available amino acids may be mixed in the above-mentioned predetermined proportions. When used as a solution, it may be dissolved in distilled water. Usually, it is powdered and mixed uniformly to form a composition, which can be dissolved in distilled water at the time of use.
  • the temperature at which the composition of the present invention is produced and stored is not particularly limited, but it is preferably produced and stored at room temperature or lower.
  • Examples of the dosage form of the anti-fatigue agent of the present invention include oral administration such as tablets, coated tablets, capsules, granules, powders, solutions, syrups, and emulsions. These various preparations are prepared by adding the excipient, binder, disintegrant, lubricant, coloring agent, flavoring agent, solubilizing agent, suspending agent, coating agent, etc. to the amino acid composition according to the present invention according to a conventional method. It can be formulated using known adjuvants that can be usually used in the field of pharmaceutical formulation.
  • the amino acid composition that is the main component of the anti-fatigue agent of the present invention is extremely safe and can be set in a wide range of dosages. In general, it can be appropriately set in consideration of various factors such as the administration route, the age, weight, and symptoms of animals to be administered including humans.
  • the present invention is not limited to this, but preferably, lg to 8 gZkgZday is appropriate as an active ingredient. It is.
  • composition of the present invention can be administered in advance when it is desired to prevent fatigue and used as an anti-fatigue agent, and can also be administered afterwards when fatigue is felt and used as a fatigue recovery agent.
  • a 3 to 6.0 wt% solution 100 to 500 ml per day may be administered 1 to 3 times.
  • the anti-fatigue agent of the present invention can be administered by any deviation from oral administration or parenteral administration (intramuscular, subcutaneous, intravenous, suppository, transdermal, etc.).
  • the anti-fatigue agent of the present invention can also be used as a special-purpose food such as a food for specified health use containing the composition, and the anti-fatigue agent of the present invention is contained in a food composition to provide a nutritional function food. By directly ingesting it as a functional food such as the above, it is possible to easily obtain an effect of preventing fatigue.
  • various foods and drinks milk, soft drinks, fermented milk, yogurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, disease
  • the anti-fatigue agent of the present invention may be added in its composition to foods for consumers, foods such as infant formula, foods such as infant formula, nutritional foods, and the like. Furthermore, it can be used in accordance with conventional methods for ordinary food yarns and adult products such as other foods and mixed with food ingredients.
  • the state of the food or drink usually used for example, solid (powder, granule, etc.), paste, liquid or suspension may be used.
  • the other components are not particularly limited, but for example, foods and drinks included in the food composition include water, proteins, carbohydrates, lipids, and vitamins. Minerals, organic acids, organic bases, fruit juices, flavors and the like can be used as ingredients.
  • proteins include whole milk powder, skim milk powder, partially skim milk powder, force zein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, j8-lacto Globulin, ⁇ -ratatoanolbumin, ratatofurin, soy protein, egg protein, meat protein, etc. And various milk-derived components.
  • lipids include animal oils such as lard and fish oil, fractionated oils, hydrogenated oil, transesterified oil, and the like; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples thereof include vegetable oils such as hydrogenated oil and ester exchange oil.
  • vitamins for example, vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin!
  • vitamin Q vitamin Q
  • niacin nicotinic acid
  • pantothenic acid biotin, inositol
  • minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium and the like.
  • organic acid include malic acid, citrate, lactic acid, tartaric acid, and the like.
  • mice Male, 8 weeks old, C57BLZ6N, rearing environment: 23 ⁇ 3 ° C, 12 hours light / dark cycle
  • mice Male, 8 weeks old, C57BLZ6N, rearing environment: 23 ⁇ 3 ° C, 12 hours light / dark cycle
  • mice were allocated so that the weight of each group was as uniform as possible, and each group had 3 to 4 samples. It was divided into a group (Example) and a control group (Comparative example). They were forcibly orally administered with the fatigue inhibitor of the present invention or physiological saline as a control without fasting.
  • One hour after administration, exercise load was applied by a treadmill test (25 mZmin for 60 minutes).
  • the dose was 500 mgZkg body weight in terms of amino acid (5% suspension was administered at 10 ⁇ LZg body weight).
  • the amino acid composition of the anti-fatigue agent of the present invention administered here is shown in Table 1 (the amino acid composition values are expressed in parts by weight).
  • Examples 1 to 6 of the present invention increases in the concentrations of cortisol, IFN-y, and IL-10 are remarkably suppressed. Since these compounds increase in concentration in proportion to the increase in fatigue, they can be evaluated as alternative indicators of mental fatigue. That is, in Examples 1 to 6 of the present invention, also in the effect of preventing mental fatigue. It turns out that it has a high effect. Further, it can be seen that this tendency appears more remarkably in Examples 5 and 6.
  • the anti-fatigue agent comprising the amino acid yarn according to the present invention can provide a high anti-fatigue effect that simultaneously prevents both muscular fatigue and mental fatigue.
  • it is a composition consisting of fewer types of amino acids, so that the number of raw material types required for preparation is reduced and industrial production is reduced. In addition, it has an excellent economic effect. Therefore, the industrial utility value is high.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

La présente invention concerne un agent anti-fatigue capable de prévenir simultanément la fatigue musculaire et la fatigue nerveuse. Selon l'invention, la prévention simultanée de la fatigue musculaire et de la fatigue nerveuse est possible avec un agent anti-fatigue contenant une composition d'acides aminés comprenant des types et des quantités spécifiques d'acides aminés. En ce qui concerne les types et les rapports quantitatifs des acides aminés préférés, ladite composition d'acides aminés contient de 30 à 200 parties en masse de proline, de 60 à 140 parties en masse de glycine, de 25 à 260 parties en masse d'alanine, de 40 à 130 parties en masse de lysine, de 20 à 75 parties en masse de tryptophane et de 15 à 40 parties en masse d'histidine. En outre, elle contient de préférence de 35 to 65 parties en masse de thréonine, de 15 à 65 parties en masse de tyrosine et de 25 à 45 parties en masse d'arginine, et en outre, elle contient de préférence de 30 à 55 parties en masse de valine, de 35 à 60 parties en masse de leucine et de 25 à 45 parties en masse d'isoleucine.
PCT/JP2007/061879 2006-06-13 2007-06-13 Agent anti-fatigue contenant une composition d'acides aminés Ceased WO2007145239A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008521230A JP5775657B2 (ja) 2006-06-13 2007-06-13 アミノ酸組成物を含有する疲労防止剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-163683 2006-06-13
JP2006163683 2006-06-13

Publications (1)

Publication Number Publication Date
WO2007145239A1 true WO2007145239A1 (fr) 2007-12-21

Family

ID=38831753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/061879 Ceased WO2007145239A1 (fr) 2006-06-13 2007-06-13 Agent anti-fatigue contenant une composition d'acides aminés

Country Status (4)

Country Link
JP (2) JP5775657B2 (fr)
KR (1) KR20090019813A (fr)
CN (1) CN101454000A (fr)
WO (1) WO2007145239A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009057775A1 (fr) * 2007-10-31 2009-05-07 Meiji Dairies Corporation Agent antifatigue comprenant une composition d'acides aminés
WO2009104696A1 (fr) * 2008-02-19 2009-08-27 株式会社アーネストメディスン Composition orale ou entérale utile pour la récupération de fonctions physiques
JPWO2010041647A1 (ja) * 2008-10-06 2012-03-08 株式会社明治 アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤
JP2013060406A (ja) * 2011-09-15 2013-04-04 Kyowa Hakko Bio Co Ltd 脳疲労改善用経口剤
JPWO2012169600A1 (ja) * 2011-06-07 2015-02-23 味の素株式会社 アミノ酸組成物
JP2015120715A (ja) * 2006-06-13 2015-07-02 株式会社明治 アミノ酸組成物を含有する疲労防止剤
JP2016014007A (ja) * 2014-06-13 2016-01-28 花王株式会社 筋タンパク質合成シグナル活性化剤
JP2016121194A (ja) * 2016-04-05 2016-07-07 協和発酵バイオ株式会社 脳疲労改善用経口剤
JPWO2015053337A1 (ja) * 2013-10-09 2017-03-09 味の素株式会社 ヒスチジンを含有する食品およびその用途
EP3466434A4 (fr) * 2016-05-26 2020-01-22 Profeat Biotechnology Co. Ltd. Utilisation d'une composition comprenant un chélate d'acide aminé ferreux pour la fabrication d'un médicament pour réduire l'acide lactique
US11045437B2 (en) 2018-08-27 2021-06-29 Ajinomoto Co., Inc. Composition for improving brain function
EP3991791A4 (fr) * 2019-06-25 2023-07-12 Ajinomoto Co., Inc. Mélange d'acides aminés présentant une structure co-amorphe

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104509919A (zh) * 2013-09-30 2015-04-15 张自力 一种功能性营养素饮料
MX2020001765A (es) * 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
KR102235563B1 (ko) 2020-08-26 2021-04-02 (주)이삼오구 고함량 아르기닌을 포함하는 피로회복 및 성기능 개선용 조성물
JP7414676B2 (ja) * 2020-09-14 2024-01-16 株式会社東芝 負荷推定装置、方法およびプログラム
JP7462127B1 (ja) 2023-08-16 2024-04-05 株式会社Healthy Body 筋肥大用組成物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
JPH0725838A (ja) * 1993-05-13 1995-01-27 Yotsuba Yuka Kk 疲労の予防または回復のための経口投与剤
JP2518692B2 (ja) * 1989-06-14 1996-07-24 理化学研究所 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
JPH08198748A (ja) * 1995-01-27 1996-08-06 Ajinomoto Co Inc アミノ酸栄養組成物
JPH09249556A (ja) * 1996-01-09 1997-09-22 Rikagaku Kenkyusho アミノ酸組成物
JP2001226272A (ja) * 2000-02-18 2001-08-21 Zeria Pharmaceut Co Ltd クエン酸及びローヤルゼリーを配合した内服液剤
WO2004028528A1 (fr) * 2002-09-30 2004-04-08 Riken Compositions d'acides amines destinees a ameliorer les fonctions centrales
JP2004352696A (ja) * 2003-05-30 2004-12-16 Institute Of Physical & Chemical Research アミノ酸組成物及び補液

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4009682B2 (ja) * 1993-05-28 2007-11-21 独立行政法人理化学研究所 アドレナリン及びノルアドレナリン分泌促進組成物
JP4280310B2 (ja) * 1995-08-10 2009-06-17 佐々木化学工業株式会社 アミノ酸組成剤
JP2000009717A (ja) * 1998-02-27 2000-01-14 Taisho Pharmaceut Co Ltd 滋養強壮効果の評価方法
JP3838038B2 (ja) * 2001-02-05 2006-10-25 株式会社豊田中央研究所 心身状態評価方法、商品又は環境の感性的品質の評価方法、評価用測定キット及び商品又は環境の品質表示方法
JP2003207495A (ja) * 2002-01-10 2003-07-25 Toyota Central Res & Dev Lab Inc 心理状態判定装置
AU2003271144A1 (en) * 2002-10-11 2004-05-04 Ajinomoto Co., Inc. Food compositions for recovery from fatigue
GB0400031D0 (en) * 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
WO2005078448A1 (fr) * 2004-02-17 2005-08-25 Soiken Inc. Appareil servant a evaluer le degre de fatigue, procede d'evaluation du degre de fatigue et utilisation de celui-ci
JP2005239579A (ja) * 2004-02-24 2005-09-08 Ajinomoto Co Inc 疲労回復剤及び疲労回復用食品
KR20090019813A (ko) * 2006-06-13 2009-02-25 메이지 데어리즈 코포레이션 아미노산 조성물을 함유하는 피로 방지제

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
JP2518692B2 (ja) * 1989-06-14 1996-07-24 理化学研究所 筋力持続剤，滋養強壮剤，輸液用剤，栄養補給剤，疲労回復剤及び乳酸生成調節剤
JPH0725838A (ja) * 1993-05-13 1995-01-27 Yotsuba Yuka Kk 疲労の予防または回復のための経口投与剤
JPH08198748A (ja) * 1995-01-27 1996-08-06 Ajinomoto Co Inc アミノ酸栄養組成物
JPH09249556A (ja) * 1996-01-09 1997-09-22 Rikagaku Kenkyusho アミノ酸組成物
JP2001226272A (ja) * 2000-02-18 2001-08-21 Zeria Pharmaceut Co Ltd クエン酸及びローヤルゼリーを配合した内服液剤
WO2004028528A1 (fr) * 2002-09-30 2004-04-08 Riken Compositions d'acides amines destinees a ameliorer les fonctions centrales
JP2004352696A (ja) * 2003-05-30 2004-12-16 Institute Of Physical & Chemical Research アミノ酸組成物及び補液

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOBAYASHI H.: "Sports to Amino Acid Supplement.", SHOKU NO KAGAKU, no. 225, 1999, pages 88 - 93, XP003000462 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015120715A (ja) * 2006-06-13 2015-07-02 株式会社明治 アミノ酸組成物を含有する疲労防止剤
WO2009057775A1 (fr) * 2007-10-31 2009-05-07 Meiji Dairies Corporation Agent antifatigue comprenant une composition d'acides aminés
AU2008319747B2 (en) * 2007-10-31 2013-04-18 Meiji Co., Ltd. Anti-fatigue agent comprising amino acid composition
JP2014129394A (ja) * 2007-10-31 2014-07-10 Meiji Co Ltd アミノ酸組成物を含有する疲労防止剤
WO2009104696A1 (fr) * 2008-02-19 2009-08-27 株式会社アーネストメディスン Composition orale ou entérale utile pour la récupération de fonctions physiques
US8778410B2 (en) 2008-02-19 2014-07-15 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
JPWO2010041647A1 (ja) * 2008-10-06 2012-03-08 株式会社明治 アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤
JPWO2012169600A1 (ja) * 2011-06-07 2015-02-23 味の素株式会社 アミノ酸組成物
JP2013060406A (ja) * 2011-09-15 2013-04-04 Kyowa Hakko Bio Co Ltd 脳疲労改善用経口剤
JPWO2015053337A1 (ja) * 2013-10-09 2017-03-09 味の素株式会社 ヒスチジンを含有する食品およびその用途
JP2016014007A (ja) * 2014-06-13 2016-01-28 花王株式会社 筋タンパク質合成シグナル活性化剤
JP2016121194A (ja) * 2016-04-05 2016-07-07 協和発酵バイオ株式会社 脳疲労改善用経口剤
EP3466434A4 (fr) * 2016-05-26 2020-01-22 Profeat Biotechnology Co. Ltd. Utilisation d'une composition comprenant un chélate d'acide aminé ferreux pour la fabrication d'un médicament pour réduire l'acide lactique
US11045437B2 (en) 2018-08-27 2021-06-29 Ajinomoto Co., Inc. Composition for improving brain function
EP3991791A4 (fr) * 2019-06-25 2023-07-12 Ajinomoto Co., Inc. Mélange d'acides aminés présentant une structure co-amorphe

Also Published As

Publication number Publication date
CN101454000A (zh) 2009-06-10
JP2015120715A (ja) 2015-07-02
JP5775657B2 (ja) 2015-09-09
JPWO2007145239A1 (ja) 2009-11-05
KR20090019813A (ko) 2009-02-25

Similar Documents

Publication Publication Date Title
JP5775657B2 (ja) アミノ酸組成物を含有する疲労防止剤
JP5775668B2 (ja) アミノ酸組成物を含有する疲労防止剤
JP5574561B2 (ja) 総合経腸栄養組成物
US20210275582A1 (en) Composition of nutrition supplementation for nutritional deficiencies and method of use therefore
AU2012299126B2 (en) Compositions and methods for use in promoting lean body mass
JP6948103B2 (ja) フレイル改善用組み合わせ物
JP2016102064A (ja) 脂質代謝促進剤
Komorowski et al. Inositol-Stabilized Arginine Silicate: A Novel Nitric Oxide-Boosting Ingredient for Sports Nutrition and Improved Cognition
JP2019099498A (ja) 脂質代謝促進のための組成物
JP2019099497A (ja) 肝機能改善のための組成物
HK1127730A (en) Anti-fatigue agent containing amino acid composition
JP2019058140A (ja) 栄養組成物
JP2023530485A (ja) 運動なしで、筋量、筋力および筋機能を改善するためのβ－ヒドロキシ－β－メチルブチレート（ＨＭＢ）の組成物および使用法
JP2016094466A (ja) 運動機能改善剤
HK1144549A (en) Anti-fatigue agent comprising amino acid composition
JP2019099495A (ja) 血圧降下促進のための組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780019510.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07767105

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020087029275

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008521230

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07767105

Country of ref document: EP

Kind code of ref document: A1